3 Russell 2000 Stocks Worth Your Attention
Spotting the best opportunities in the Russell 2000 takes research, and we're here to do the heavy lifting for you. That said, here are three Russell 2000 stocks that could be the next big thing.
Market Cap: $3.39 billion
Founded by Caltech professor Carver Mead and one of his students Chris Diorio, Impinj (NASDAQ:PI) is a maker of radio-frequency identification (RFID) hardware and software.
Why Does PI Catch Our Eye?
Annual revenue growth of 11.9% over the past two years was outstanding, reflecting market share gains this cycle
Performance over the past five years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 38.1% outpaced its revenue gains
Free cash flow margin expanded by 23.7 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
Impinj is trading at $117 per share, or 73x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free.
Market Cap: $12.97 billion
Focused on the future of autonomous military combat, AeroVironment (NASDAQ:AVAV) specializes in advanced unmanned aircraft systems and electric vehicle charging solutions.
Why Do We Watch AVAV?
Annual revenue growth of 23.2% over the past two years was outstanding, reflecting market share gains this cycle
Exciting sales outlook for the upcoming 12 months calls for 144% growth, an acceleration from its two-year trend
Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 63.4% annually
At $263.71 per share, AeroVironment trades at 68.2x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free.
Market Cap: $1.34 billion
Founded in 1884 and serving communities from Mendocino County in the north to Kern County in the south, Westamerica Bancorporation (NASDAQ:WABC) provides banking services to individuals and small businesses throughout Northern and Central California.
Why Could WABC Be a Winner?
Solid 9.7% annual net interest income growth over the last four years indicates its offerings are gaining share
Efficiency ratio improved by 11.4 percentage points over the last four years as it scaled
Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
Westamerica Bancorporation's stock price of $51.12 implies a valuation ratio of 1.4x forward P/B. Is now a good time to buy? Find out in our full research report, it's free.
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Smith & Wesson Brands, Inc. (SWBI) Is Down 23% In One Month. Here Is Why
Smith & Wesson Brands, Inc. (NASDAQ:SWBI) is among the 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds. The company is a leading maker of long guns, handguns, rifles, and other shooting equipment. An overhead aerial shot of a gunsmiths workshop, surrounded by tools of the trade. SWBI's shares are down 23% over the past month, with a major dip following the announcement of fourth quarter 2025 results on June 18. Net sales were reported at $140.8 million, down 11.6% year-over-year, while non-GAAP net income declined from $22.1 million in the prior year to $9 million this year. Gross margin stood at 28.8%, compared to 35.5% last year. Smith & Wesson Brands, Inc. (NASDAQ:SWBI)'s President and CEO, Mark Smith, cited industry trends and macroeconomic challenges as the reasons behind a difficult quarter. However, the company was able to offset the bottom-line impact by leveraging its flexible manufacturing model and by ensuring disciplined cost management. While the current market conditions suggest the headwinds are likely to persist in the near term, the management remains optimistic about Smith & Wesson Brands, Inc. (NASDAQ:SWBI) being well-positioned to succeed. New products continue to perform well, which has enabled the company to maintain its dominant position in the firearms market. Following the results, analysts at Lake Street lowered Smith & Wesson Brands, Inc. (NASDAQ:SWBI)'s price target to $11 from $12.5, but maintained a Buy rating for its shares. While we acknowledge the potential of SWBI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
MINNEAPOLIS, July 21, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 8,606,426 common shares at a purchase price of $3.50 per share. The private placement is expected to close on or about July 23, 2025, subject to the satisfaction of customary closing conditions. The capital raised is expected to fund the Company's operations for more than two years and support upcoming milestones including the submission of an investigational new drug (IND) application in the United States for preeclampsia and fetal growth restriction and a Phase 2b study to further evaluate DM199 in both indications, pending IND approval. "This financing allows us to rapidly accelerate our development efforts in preeclampsia and fetal growth restriction, both of which have no approved treatment options currently," said Rick Pauls, President and CEO of DiaMedica. "We believe DM199 has the potential to be a disease-modifying therapy for these patients, and look forward to building upon what is already the most advanced clinical program targeting these conditions." The offer and sale of the common shares in the private placement have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and such common shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state and other securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the foregoing securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Required Canadian Related Party Transaction Disclosure DiaMedica has received binding commitments for participation in the private placement from certain non-management, related parties, in the aggregate amount of $30.1 million or 8,606,426 common shares. Accordingly, the private placement constitutes a "related party transaction" as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101") of the Canadian Securities Administrators. The private placement will be exempt from the valuation and the minority shareholder approval requirements of MI 61-101 under the exemptions contained in section 5.5(a) and 5.7(1)(a), respectively, as neither the fair market value of the common shares nor the fair market value of the consideration paid for the common shares insofar as it involves the related parties is more than 25% of the Company's market capitalization. About DM199 (rinvecalinase alfa) DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia, fetal growth restriction and acute ischemic stroke. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor. In preeclampsia and fetal growth restriction, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta while for stroke intended to increase collateral circulation in the penumbra following a stroke. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "seek," "might," "project," "target," "aim," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company's expectations regarding its expected cash runway and ability to obtain and complete a Phase 2b study in preeclampsia, the anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke, and the continued ReMEDy2 trial enrollment and the timing of the interim analysis on the first 200 participants in the first half of 2026. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to risks and uncertainties relating to the clinical expansion into preeclampsia and that trial; the timing of ReMEDy2 trial enrollment, regulatory applications and related filing and approval timelines; the possibility that enrollment in the ReMEDy2 trial will not continue to increase as anticipated; the possibility of additional future adverse events associated with or unfavorable results from the ReMEDy2 trial; the possibility of unfavorable results from DiaMedica's other ongoing or future clinical trials of DM199; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; DiaMedica's plans to develop, obtain regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia and acute ischemic stroke and its expectations regarding the benefits of DM199; DiaMedica's ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the adaptive design of the ReMEDy2 trial and the possibility that the targeted enrollment and other aspects of the trial could change depending upon certain factors, including additional input from the FDA and the blinded interim analysis; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica's business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica's reliance on collaboration with third parties to conduct clinical trials; DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. View source version on Contacts Corporate Contact: Scott Kellen, Chief Financial Officer(763) 496-5118 | skellen@ Investor Contact: Mike Moyer, Managing Director, LifeSci Advisorsmmoyer@ Media Contact: Madelin Hawtin, LifeSci Communicationsmhawtin@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a few seconds ago
- Yahoo
Here Is What You Need To Know Before Investing In Byrna Technologies Inc. (BYRN)
Byrna Technologies Inc. (NASDAQ:BYRN) is among the 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds. The company manufactures less-lethal equipment and munitions for personal security, private security firms, and law enforcement agencies. A military personnel in gear next to a shoulder-fired launcher, representing the company's less-lethal defense technology. In March of this year, the firm announced the opening of its ammunition manufacturing facility in the United States, located in Fort Wayne, Indiana, just five miles from its launcher production facility. The expansion has advanced Byrna Technologies Inc. (NASDAQ:BYRN)'s transition to domestic manufacturing. It also positions the company well to meet growing demand, given the facility's capacity to produce 8 million rounds of its proprietary less-lethal ammunition per annum. On July 10, Byrna Technologies Inc. (NASDAQ:BYRN) announced strong results for the second quarter of fiscal 2025, with revenue climbing 41% year-over-year to a record $28.5 million, driven by the launch of the new Compact Launcher (CL), broader brand adoption, and increased dealer and chain store sales. Net income was posted at $2.4 million, up 14% from the prior year's period. Despite the robust results, Byrna Technologies Inc. (NASDAQ:BYRN)'s shares plunged by 29% in the five days following the earnings call. The significant dip suggests a 'sell the news' reaction from investors, who sold the stock, believing that the results may have been priced into its share price. Byrna Technologies Inc. (NASDAQ:BYRN)'s shares have been volatile in 2025. While the stock is down 20% YTD, it had an impressive run between April and July, nearly doubling during the period. While we acknowledge the potential of BYRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
